Skip to main content
Genome&Company logo

Genome&Company — Investor Relations & Filings

Ticker · 314130 ISIN · KR7314130006 KO Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2024-01-11 Major Shareholding Noti…
Country KR South Korea
Listing KO 314130

About Genome&Company

http://genomecom.co.kr/

Genome&Company is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics. The company's research and development pipeline is centered on two primary platforms: microbiome-based pharmaceuticals and novel immune checkpoint inhibitors for immuno-oncology. Its drug candidates are derived from its proprietary microbiome platform and are aimed at treating a range of diseases, with a significant focus on cancer. In addition to its pharmaceutical programs, the company develops and markets consumer healthcare products, including dietary supplements and cosmeceuticals, leveraging its expertise in microbes and probiotics.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a regulatory filing required under the Capital Markets Act in South Korea when an entity's shareholding in a listed company crosses certain thresholds. This specific document details the changes in share ownership by DSC Investment in Genome & Company. It is a formal disclosure of major shareholding changes, not an announcement of a report, and fits the definition of a Major Shareholding Notification.
2024-01-11 Korean
투자판단관련주요경영사항(임상시험계획승인신청등결정)(신규타깃 면역항암제 GENA-104의 제1상 임상시험계획(IND) 승인)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (Genome & Company) regarding the approval of a Phase 1 clinical trial (IND) by the Ministry of Food and Drug Safety (MFDS). This type of disclosure, which reports a material business event (clinical trial approval), does not fit into specific categories like financial reports, dividends, or director dealings. Therefore, it is classified as a general regulatory filing (RNS).
2024-01-10 Korean
기타경영사항(자율공시)(전환우선주의 보통주 전환청구)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from Genome & Company regarding the conversion of convertible preferred shares into common shares. This involves a change in the company's capital structure and share count. According to the provided definitions, announcements regarding new share issues or capital changes fall under the 'Share Issue/Capital Change' (SHA) category.
2024-01-03 Korean
임시주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '임시주주총회결과' (Extraordinary General Meeting Results) and provides the outcome of specific agenda items (voting results) from a shareholder meeting held on 2023-12-28. This falls directly under the definition of a Declaration of Voting Results.
2023-12-28 Korean
본점소재지변경
Regulatory Filings Classification · 100% confidence The document is a short, formal announcement regarding a change in the company's registered office address (본점소재지변경). It provides specific details about the old and new addresses, the reason for the change, and the effective date. Since this is a standard regulatory disclosure regarding corporate administrative changes that does not fit into specific financial reporting categories like 10-K, IR, or ER, it is classified as a general regulatory filing.
2023-12-28 Korean
기타경영사항(자율공시)(전환우선주의 보통주 전환청구)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from Genome & Company regarding the conversion of convertible preferred shares into common shares. This involves a change in the company's capital structure (number of shares and capital amount). According to the filing definitions, 'SHA' (Share Issue/Capital Change) covers announcements regarding new share issues or capital changes resulting from conversions. While it is a voluntary disclosure, it specifically details the issuance of new common shares and the reduction of preferred shares, fitting the 'SHA' category perfectly.
2023-12-22 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.